GH (Guardant360) Net earnings per one share for the last twelve months

The implementation of Shield for colorectal cancer screening is driving sales, as confirmed by the year-over-year EPS (TTM) comparison for Guardant Health, Inc. (GH). Meanwhile, cloud-based bioinformatics outsourcing is creating IT dependency, while geopolitical sanctions are hindering global research. This chart smooths out the noise between reports, with the -14.60 metric serving as the target level for assessing earnings per share dynamics.
Guardant Corp - analytical breakdowns and key metrics (GH)

Analyzing earnings per share (EPS) dynamics is critical for selecting assets with a high margin of safety. This indicator captures the annual growth rate of trailing twelve-month (TTM) net income, enabling an assessment of Guardant Health, Inc. (GH) commercialization efficiency for its oncology diagnostic tests and the success of their integration into government programs by measuring the annual EPS TTM growth.